アンチセンスおよびRNAi治療薬市場：世界の産業規模、シェア、動向、機会、予測、技術別、用途別、投与経路別、地域別、競合別セグメント、2019年～2029年

アンチセンスおよびRNAi治療薬の世界市場規模は2023年に45億7,000万米ドルとなり、2029年までの予測期間のCAGRは18.45%で堅調な成長が予測されています。

世界のアンチセンスおよびRNAi治療薬市場は、力強い成長と技術的進歩に特徴づけられる変革期を迎えています。アンチセンスおよびRNA干渉（RNAi）療法は、分子医学分野における最先端のアプローチであり、遺伝子レベルでの標的化された正確な介入を提供します。この市場の拡大には、疾患の遺伝的基盤に対する理解の深まりと、治療効果を得るために遺伝子発現を調節するこれらの治療法の可能性が背景にあります。市場を促進する要因の一つは、遺伝性疾患や慢性疾患の有病率の増加です。アンチセンスおよびRNAi治療薬は、遺伝的要素を持つ疾患の治療に有望な手段を提供し、遺伝子発現を修正または調節して疾患の根本原因に対処する可能性を提供します。RNAi技術の継続的な進化は、より効率的な送達システムの開拓と特異性の強化によって、市場の成長をさらに加速させています。ナノ粒子をベースとしたデリバリー、脂質をベースとしたキャリア、その他の革新的な戦略の進歩は、この分野における歴史的な課題を克服し、アンチセンスおよびRNAi治療薬のバイオアベイラビリティと標的デリバリーの改善に貢献しています。臨床試験のパイプラインの拡大と新規治療薬の承認は、この市場の勢いを裏付けています。製薬会社は、希少な遺伝性疾患から様々ながんに至るまで、幅広い疾患を対象とした革新的なRNAベースの治療法を最前線に送り出すため、研究開発への投資をますます増やしています。アンチセンスおよびRNAi治療薬の多用途性により、腫瘍学、神経学、感染症、希少遺伝子疾患など、多様な治療領域への応用が可能となります。これらの治療法の個別化された標的化された性質は、個々の遺伝子プロファイルに基づいて治療を調整する精密医療アプローチの有望な候補として位置づけられています。しかしながら、オフターゲット効果、デリバリーの複雑さ、デリバリーシステムの改良の必要性などの課題は依然として残っています。現在進められている調査や学界と産業界の共同研究は、これらの課題に対処することを目的としており、市場をさらに前進させるものです。

市場促進要因

遺伝性疾患および慢性疾患の有病率の増加

RNAi技術の技術的進歩

臨床試験パイプラインの拡大

主な市場課題

デリバリーの複雑さ

免疫原性

主要市場動向

デリバリー技術の進歩

臨床試験の増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のアンチセンスおよびRNAi治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別（RNA干渉、アンチセンスRNA）
  • 用途別（眼疾患、心血管代謝・腎臓疾患、がん、呼吸器疾患、皮膚疾患、神経変性疾患、遺伝性疾患、感染症）
  • 投与経路別（静脈内注射、髄腔内注射、皮下注射、その他）
  • 地域別
  • 企業別（2023年）
• 市場マップ
  • 技術別
  • 用途別
  • 投与経路別
  • 地域別

第6章 アジア太平洋地域のアンチセンスおよびRNAi治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 用途別
  • 投与経路別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州のアンチセンスおよびRNAi治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 用途別
  • 投与経路別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米のアンチセンスおよびRNAi治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 用途別
  • 投与経路別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米のアンチセンスおよびRNAi治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 用途別
  • 投与経路別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのアンチセンスおよびRNAi治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 用途別
  • 投与経路別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のアンチセンスおよびRNAi治療薬市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Olix Pharmaceuticals, Inc.
• GSK plc
• Sanofi Aventis S.A.
• Alnylam Pharmaceuticals, Inc.
• Ionis Pharmaceuticals, Inc.
• Benitec Biopharma Inc
• Silence Therapeutics Inc.
• Arbutus Biopharma Inc.
• Sarepta Therapeutics Inc.
• Percheron Therapeutics Limited

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Antisense And RNAi Therapeutics Market was valued at USD 4.57 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 18.45% through 2029. The Global Antisense and RNAi Therapeutics Market is experiencing a transformative phase, marked by robust growth and technological advancements. Antisense and RNA interference (RNAi) therapies represent a cutting-edge approach in the field of molecular medicine, offering targeted and precise interventions at the genetic level. This market's expansion is driven by a growing understanding of the genetic basis of diseases and the potential of these therapies to modulate gene expression for therapeutic benefits. One of the key drivers propelling the market is the increasing prevalence of genetic disorders and chronic diseases. Antisense and RNAi therapeutics provide a promising avenue for treating conditions with a genetic component, offering the potential to correct or regulate gene expression and address the underlying causes of diseases. The continuous evolution of RNAi technology, with the development of more efficient delivery systems and enhanced specificity, further accelerates market growth. Advancements in nanoparticle-based delivery, lipid-based carriers, and other innovative strategies contribute to improving the bioavailability and targeted delivery of antisense and RNAi therapeutics, overcoming historical challenges in this field. The expanding pipeline of clinical trials and the approval of novel therapies underscore the momentum in this market. Pharmaceutical companies are increasingly investing in research and development to bring innovative RNA-based therapies to the forefront, targeting a broad spectrum of diseases ranging from rare genetic disorders to various cancers. The versatility of antisense and RNAi therapeutics allows for their application in diverse therapeutic areas, including oncology, neurology, infectious diseases, and rare genetic conditions. The personalized and targeted nature of these therapies positions them as promising candidates for precision medicine approaches, tailoring treatments based on individual genetic profiles. However, challenges such as off-target effects, delivery complexities, and the need for refining delivery systems persist. Ongoing research endeavors and collaborations between academia and industry aim to address these challenges, further propelling the market forward.

Key Market Drivers

Increasing Prevalence of Genetic and Chronic Diseases

The Global Antisense and RNAi Therapeutics Market are witnessing significant growth, driven in part by the increasing prevalence of genetic and chronic diseases. As the global healthcare landscape grapples with a surge in genetic disorders and chronic conditions, the demand for innovative therapeutic solutions has intensified. Antisense and RNA interference (RNAi) therapies have emerged as promising avenues for addressing the underlying genetic causes of diseases. With their ability to modulate gene expression, these advanced therapies offer targeted interventions, providing hope for patients with conditions that were traditionally challenging to treat. Genetic disorders, ranging from rare conditions to more common hereditary diseases, have garnered increased attention due to advancements in genomic research. Similarly, the escalating incidence of chronic diseases, such as certain cancers and neurodegenerative disorders, underscores the urgent need for breakthrough treatments. Antisense and RNAi therapeutics, with their precision in targeting specific genes and pathways, present a transformative approach to managing and potentially reversing the course of these diseases. The market's response to the growing prevalence of genetic and chronic diseases reflects a paradigm shift towards personalized medicine. Tailoring treatments based on individual genetic profiles aligns with the targeted nature of antisense and RNAi therapies, positioning them as pivotal players in the evolving landscape of molecular medicine. As research and development efforts continue to advance, the Global Antisense and RNAi Therapeutics Market is poised to play a crucial role in addressing the healthcare challenges posed by genetic and chronic diseases on a global scale.

Technological Advancements in RNAi Technology

The Global Antisense and RNAi Therapeutics Market are experiencing dynamic growth, fueled in significant part by continuous technological advancements in RNA interference (RNAi) technology. The landscape of RNAi has undergone substantial transformation, marked by innovations addressing historical challenges and enhancing the efficacy of therapeutic interventions. Key to these advancements are improvements in delivery systems, which have historically posed obstacles to the clinical translation of RNA-based therapies. Novel formulations, including lipid-based carriers and nanoparticle-based delivery methods, have contributed to overcoming hurdles related to bioavailability and target specificity. The increased precision in targeting specific genes and pathways has been a hallmark of these technological breakthroughs. Enhanced specificity ensures that RNAi therapeutics selectively modulate the expression of the intended genes, minimizing off-target effects and improving overall treatment outcomes. The ability to fine-tune the delivery of RNA-based therapeutics has expanded their applicability across a broader spectrum of diseases, ranging from genetic disorders to various cancers. The refinement of RNAi technology has facilitated the development of next-generation therapies with improved pharmacokinetics and enhanced cellular uptake. These innovations are crucial for translating the immense potential of RNA-based therapeutics into tangible clinical benefits. As the field continues to evolve, with researchers exploring novel delivery mechanisms and RNA modifications, the technological progress in RNAi technology is positioning the Global Antisense and RNAi Therapeutics Market at the forefront of precision medicine and targeted therapeutic interventions. The continuous refinement of these technologies holds promise for the development of increasingly efficient and versatile RNAi-based therapies with broader clinical applications.

Expanding Pipeline of Clinical Trials

The Global Antisense and RNAi Therapeutics Market are undergoing a significant expansion, driven by a burgeoning pipeline of clinical trials. This surge in clinical research underscores the increasing interest and investment in antisense and RNA interference (RNAi) therapies, positioning them as transformative interventions for a diverse array of medical conditions. Pharmaceutical companies and biotechnology firms are actively conducting trials to evaluate the safety and efficacy of these innovative therapies across various therapeutic areas, including oncology, neurology, infectious diseases, and rare genetic disorders. The expanding pipeline signifies a commitment to exploring the potential of antisense and RNAi therapeutics in addressing unmet medical needs. Clinical trials play a pivotal role in advancing the understanding of these therapies, paving the way for their eventual commercialization and widespread adoption. As researchers delve into novel applications and combinations of RNA-based interventions, the clinical landscape is evolving rapidly. The regulatory agencies' receptiveness to these advancements has facilitated the progression of antisense and RNAi therapies through clinical development stages. The collaborative efforts between industry and regulatory bodies contribute to streamlining the path to market approval. This robust clinical pipeline not only reflects the increasing confidence in the therapeutic potential of antisense and RNAi technologies but also offers hope for patients with conditions that were historically challenging to treat. As more clinical trials progress through phases of testing, the Global Antisense and RNAi Therapeutics Market is poised for continued growth, marking a transformative era in the realm of precision medicine and targeted therapeutic interventions.

Key Market Challenges

Delivery Complexities

Delivery complexities represent a significant challenge in the Global Antisense and RNAi Therapeutics Market. The effective deployment of antisense oligonucleotides (ASOs) and RNA interference (RNAi) molecules to their target cells poses intricate hurdles that impact the overall success of these therapies. One primary challenge is the need to navigate biological barriers, such as cell membranes and the blood-brain barrier, which can impede the efficient transport of therapeutic agents to the intended sites of action. The ensuring optimal distribution throughout the body while avoiding off-target effects is a delicate balance that requires precise delivery systems. The delicate nature of RNA-based molecules makes them susceptible to enzymatic degradation, necessitating the development of sophisticated delivery vehicles to protect them during transit. Strategies involving lipid-based carriers, nanoparticles, and other innovative formulations aim to enhance the stability and bioavailability of antisense and RNAi therapeutics. Targeting specific tissues or organs adds another layer of complexity, as different diseases may require tailored delivery approaches. For instance, neurodegenerative diseases may demand strategies to overcome the blood-brain barrier, while systemic conditions necessitate broader distribution. Researchers and pharmaceutical companies are actively exploring innovative delivery methods to overcome these challenges. Continued advancements in nanotechnology, biomaterials, and formulation sciences are crucial in refining delivery systems, ensuring the efficient and targeted transport of antisense and RNAi therapeutics. As the field addresses these complexities, it moves closer to unlocking the full therapeutic potential of these advanced molecular interventions, contributing to the evolution of precision medicine.

Immunogenicity

Immunogenicity stands out as a significant challenge in the Global Antisense and RNAi Therapeutics Market. The potential for the human immune system to recognize antisense oligonucleotides (ASOs) and RNA interference (RNAi) molecules as foreign entities poses a risk of triggering immune responses. These responses can lead to reduced therapeutic efficacy, compromised safety, and even adverse effects. Minimizing immunogenicity is crucial to ensuring the long-term success of antisense and RNAi therapies. The unique composition of ASOs and RNAi molecules, often synthesized from synthetic or modified nucleotides, may elicit immune reactions. The body's recognition of these molecules as foreign entities can result in the production of antibodies, neutralizing the therapeutic effect and potentially causing side effects. Researchers and developers are actively engaged in strategies to mitigate immunogenic responses, including the design of chemically modified oligonucleotides to reduce recognition by the immune system. Efforts to enhance the safety and efficacy of antisense and RNAi therapeutics include exploring innovative delivery systems that not only protect these molecules during transit but also minimize immune reactions upon administration. Addressing immunogenicity challenges is crucial not only for improving patient outcomes but also for gaining regulatory approvals and fostering greater acceptance of these advanced therapies. As the Global Antisense and RNAi Therapeutics Market continues to evolve, strategies to manage immunogenicity will play a pivotal role in shaping the success and broad adoption of these innovative molecular interventions.

Key Market Trends

Advancements in Delivery Technologies

Advancements in delivery technologies are at the forefront of shaping the Global Antisense and RNAi Therapeutics Market. The success of antisense oligonucleotides (ASOs) and RNA interference (RNAi) molecules hinges on overcoming delivery complexities to ensure efficient and targeted therapeutic interventions. Researchers and pharmaceutical developers are actively exploring innovative strategies to enhance the delivery of these molecular therapies. Nanoparticle-based delivery systems, lipid-based carriers, and other formulations are witnessing significant advancements, aiming to improve the stability, bioavailability, and specificity of antisense and RNAi therapeutics. Nanoparticle-based delivery, utilizing nanocarriers such as liposomes or nanoparticles, offers a promising avenue to protect ASOs and RNAi molecules during transit, enhancing their stability and preventing degradation. Lipid-based carriers, designed to mimic natural cell membranes, facilitate efficient cellular uptake, ensuring that the therapeutic agents reach their intended targets with precision. These advancements not only address challenges related to delivery but also minimize off-target effects, enhancing the safety profile of antisense and RNAi therapies. The evolution of delivery technologies is crucial in expanding the therapeutic applications of antisense and RNAi interventions. The ability to navigate biological barriers, such as the blood-brain barrier, opens new possibilities for treating neurological disorders. As these delivery technologies continue to progress, they play a pivotal role in unlocking the full therapeutic potential of antisense and RNAi therapeutics, fostering innovation and driving the market towards precision medicine and targeted therapeutic interventions.

Increasing Clinical Trials

The Global Antisense and RNAi Therapeutics Market are experiencing a notable surge in clinical trials, signifying a robust and dynamic phase in the development and application of antisense oligonucleotides (ASOs) and RNA interference (RNAi) technologies. The growing number of clinical trials reflects heightened interest and investment from pharmaceutical companies and researchers, aiming to explore the therapeutic potential of these advanced molecular interventions. Trials are underway across diverse therapeutic areas, including oncology, neurology, infectious diseases, and rare genetic disorders, showcasing the versatility of antisense and RNAi therapies. This surge in clinical activity is instrumental in advancing the understanding of the safety, efficacy, and broader applicability of these technologies. It also underscores the commitment to addressing unmet medical needs and diversifying treatment options. The results from these trials contribute crucial data for regulatory approvals, shaping the trajectory of antisense and RNAi therapeutics toward market adoption. The increasing clinical trials are fostering collaborative efforts between industry stakeholders, regulatory bodies, and academic institutions. Partnerships and collaborations are pivotal in pooling expertise and resources, accelerating the pace of research and development. As the trials progress through different phases, the Global Antisense and RNAi Therapeutics Market is positioned for continuous growth, marked by innovations, expanded therapeutic applications, and the potential for groundbreaking treatments in diverse medical domains.

Segmental Insights

Application Insights

Based on application, respiratory disorders segment dominated the Global Antisense And RNAi Therapeutics Market in 2023. This is ascribed due to its critical need for innovative treatments in conditions like cystic fibrosis, asthma, and chronic obstructive pulmonary disease (COPD). Antisense and RNAi therapeutics show promise in targeting specific genes implicated in respiratory diseases, offering a targeted and personalized approach. The prevalence of respiratory disorders worldwide and the limited efficacy of existing treatments drive the demand for advanced therapeutics. The respiratory segment's dominance reflects the urgency to address unmet medical needs, positioning antisense and RNAi therapies as forefront candidates for treating a spectrum of respiratory conditions.

Regional Insights

North America commands dominance in the global Antisense and RNAi Therapeutics market. Firstly, the region benefits from a robust pharmaceutical and biotechnology industry with significant investments in research and development. Secondly, North America houses major players in the field, fostering innovation and driving advancements in antisense and RNAi therapies. The well-established healthcare infrastructure and a favorable regulatory environment expedite the approval and commercialization of these therapeutics. The region's access to substantial funding and a high level of healthcare awareness among both healthcare professionals and the general population further contribute to its leading position in the global market. The convergence of these factors positions North America at the forefront of Antisense and RNAi Therapeutics, influencing its dominant status.

Key Market Players

Olix Pharmaceuticals, Inc.

GSK plc

Sanofi Aventis S.A.

Alnylam Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

Benitec Biopharma Inc

Silence Therapeutics Inc.

Arbutus Biopharma Inc.

Sarepta Therapeutics Inc.

Percheron Therapeutics Limited.

Report Scope:

In this report, the Global Antisense And RNAi Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antisense And RNAi Therapeutics Market, By Technology:

RNA Interference Antisense RNA

Antisense And RNAi Therapeutics Market, By Route of Administration:

Intravenous Injections Intrathecal Injections Subcutaneous Injections Other

Antisense And RNAi Therapeutics Market, By Application:

Ocular Cardiometabolic & Renal Disorders Cancer Respiratory Disorders Skin Diseases Neurodegenerative Disorders Genetic Disorders Infectious Diseases

Antisense And RNAi Therapeutics Market, By Region:

North America
• United States
• Canada
• Mexico
Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
South America
• Brazil
• Argentina
• Colombia
Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Antisense And RNAi Therapeutics Market.

Available Customizations:

Global Antisense And RNAi Therapeutics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antisense And RNAi Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (RNA Interference, Antisense RNA)
  • 5.2.2. By Application (Ocular, Cardiometabolic & Renal Disorders, Cancer, Respiratory Disorders, Skin Diseases, Neurodegenerative Disorders, Genetic Disorders, Infectious Diseases)
  • 5.2.3. By Route of Administration (Intravenous Injections, Intrathecal Injections, Subcutaneous Injections, Other)
  • 5.2.4. By Region
  • 5.2.5. By Company (2023)
• 5.3. Market Map
  • 5.3.1. By Technology
  • 5.3.2. By Application
  • 5.3.3. By Route of Administration
  • 5.3.4. By Region

6. Asia Pacific Antisense And RNAi Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Application
  • 6.2.3. By Route of Administration
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Antisense And RNAi Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Route of Administration
  • 6.3.2. India Antisense And RNAi Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Route of Administration
  • 6.3.3. Australia Antisense And RNAi Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Route of Administration
  • 6.3.4. Japan Antisense And RNAi Therapeutics Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Technology
      • 6.3.4.2.2. By Application
      • 6.3.4.2.3. By Route of Administration
  • 6.3.5. South Korea Antisense And RNAi Therapeutics Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Technology
      • 6.3.5.2.2. By Application
      • 6.3.5.2.3. By Route of Administration

7. Europe Antisense And RNAi Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Application
  • 7.2.3. By Route of Administration
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Antisense And RNAi Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Route of Administration
  • 7.3.2. Germany Antisense And RNAi Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Route of Administration
  • 7.3.3. Spain Antisense And RNAi Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Route of Administration
  • 7.3.4. Italy Antisense And RNAi Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Route of Administration
  • 7.3.5. United Kingdom Antisense And RNAi Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Route of Administration

8. North America Antisense And RNAi Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Application
  • 8.2.3. By Route of Administration
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Antisense And RNAi Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Route of Administration
  • 8.3.2. Mexico Antisense And RNAi Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Route of Administration
  • 8.3.3. Canada Antisense And RNAi Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Route of Administration

9. South America Antisense And RNAi Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Application
  • 9.2.3. By Route of Administration
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Antisense And RNAi Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Route of Administration
  • 9.3.2. Argentina Antisense And RNAi Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Route of Administration
  • 9.3.3. Colombia Antisense And RNAi Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Route of Administration

10. Middle East and Africa Antisense And RNAi Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Application
  • 10.2.3. By Route of Administration
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Antisense And RNAi Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Route of Administration
  • 10.3.2. Saudi Arabia Antisense And RNAi Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Route of Administration
  • 10.3.3. UAE Antisense And RNAi Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Route of Administration
  • 10.3.4. Egypt Antisense And RNAi Therapeutics Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Technology
      • 10.3.4.2.2. By Application
      • 10.3.4.2.3. By Route of Administration

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Antisense And RNAi Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Olix Pharmaceuticals, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (In case of listed)
  • 15.1.5. Recent Developments
  • 15.1.6. SWOT Analysis
• 15.2. GSK plc
• 15.3. Sanofi Aventis S.A.
• 15.4. Alnylam Pharmaceuticals, Inc.
• 15.5. Ionis Pharmaceuticals, Inc.
• 15.6. Benitec Biopharma Inc
• 15.7. Silence Therapeutics Inc.
• 15.8. Arbutus Biopharma Inc.
• 15.9. Sarepta Therapeutics Inc.
• 15.10. Percheron Therapeutics Limited

16. Strategic Recommendations

17. About Us & Disclaimer